Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Hansa Biopharma AB (publ)    HNSA   SE0002148817


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Hansa Biopharma : Biopharm announces positive high-level data from investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease

09/24/2020 | 02:25pm EST

Study concludes that imlifidase leads to rapid clearance of anti-GBM antibodies, with two-thirds of patients achieving dialysis independence six months after treatment

Positive data demonstrates potential to increase renal survival in anti-GBM antibody disease and marks an important milestone for expansion of imlifidase outside transplantation

Lund, Sweden September 24, 2020. Hansa Biopharma ('Hansa'), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces positive high-level data from an investigator-initiated phase 2 trial that evaluated safety, tolerability and efficacy of imlifidase in 15 patients with severe anti-GBM antibody disease.

Anti-GBM antibody disease, also known as Goodpasture's disease, is a severe autoimmune disease where the immune system mistakenly develops IgG-antibodies directed against the glomerular basement membrane (GBM), resulting in an acute immune attack causing severe kidney injury and, in some patients, also injuring the lungs.

Anti-GBM is a rare and acute immunological disease with a significant unmet medical need that affects approximately 1.5 in a million people annually, with a majority of patients losing their kidney function and requiring chronic dialysis and kidney transplantation. In severe cases, anti-GBM antibody disease may lead to death.

The first high-level data read out has been completed and the encouraging results indicate that imlifidase treatment may lead to increased renal survival in patients with anti-GBM antibody disease due to rapid clearance of IgG antibodies. The phase 2 anti-GBM study enrolled 15 subjects, six females and nine males with a median age of 61 years of age (range 19-79 years) recruited across centers from five European countries, including Sweden, Denmark, Czech Republic, France and Austria.

At inclusion, ten of the patients were dialysis dependent, including five that were oliguric/anuric, while five patients were dialysis independent but had eGFR levels below 15 ml/min. Six hours after imflidase no patient had anti-GBM antibody levels above the normal range.

At six months, ten patients were dialysis independent (median eGFR 27 ml/min). Four patients were dialysis dependent, while one patient had died (unrelated to imlifidase treatment). The safety profile of imlifidase in the population was concluded as being favourable.

'The positive results from the phase 2 trial suggest the potential for treatment and thereby the opportunity to increase the chances of renal survival in difficult to treat patients with anti-GBM disease', says Sponsor and Coordinating Principle Investigator, Mårten Segelmark, Professor of Nephrology at Lund University and Linköping University.

'We are very encouraged by the positive outcome from the phase 2 trial in anti-GBM antibody disease. Anti-GBM is the first IgG-mediated disease outside transplantation, where imlifidase has been shown to stop an immunologic attack. This marks an important milestone in Hansa Biopharma's efforts to develop potentially lifesaving and life altering therapies for patients with rare immunological diseases within a range of therapeutic areas where there is a significant unmet medical need', says Søren Tulstrup, President and CEO, Hansa Biopharma.

Hansa Biopharma was granted orphan drug designation for imlifidase as a treatment for anti-GBM antibody disease in both the EU and the US in 2018.

Hansa Biopharma is hosting a Capital Markets Day planned for October 29, 2020 in Copenhagen, where more information from the anti-GBM phase 2 trial will be presented. For more information and registration for this event, click here.

This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through th the contact person set out above at 20:15 CET on September 24, 2020.

Multimedia Files:



Hansa Biopharma AB published this content on 24 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 September 2020 18:24:03 UTC

© Publicnow 2020
01/11HANSA BIOPHARMA : Forecasts FY20 Operating Loss to Widen
01/11HANSA BIOPHARMA : provides business update incl. certain key financials ahead of..
2020HANSA BIOPHARMA :  Biopharma to present at the 39th Annual J.P. Morgan Healthcar..
2020HANSA BIOPHARMA : Nomination Committee formed
2020Hansa Biopharma interim report Jan-Sep 2020
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
2020HANSA BIOPHARMA : certified as a Great Place to Work
More news
Sales 2020 35,8 M 4,29 M 4,29 M
Net income 2020 -396 M -47,5 M -47,5 M
Net cash 2020 1 385 M 166 M 166 M
P/E ratio 2020 -20,2x
Yield 2020 -
Capitalization 8 468 M 1 010 M 1 015 M
EV / Sales 2020 198x
EV / Sales 2021 77,3x
Nbr of Employees 80
Free-Float 95,9%
Duration : Period :
Hansa Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANSA BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 295,67 SEK
Last Close Price 190,40 SEK
Spread / Highest target 115%
Spread / Average Target 55,3%
Spread / Lowest Target -0,21%
EPS Revisions
Managers and Directors
Søren Tulstrup President & Chief Executive Officer
Ulf Arne Wiinberg Chairman
Christian Kjellman Chief Operating & Scientific Officer
Donato Spota Chief Financial Officer
Achim Kaufhold Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.24.10%51 304
LONZA GROUP AG2.46%48 618
CELLTRION, INC.-12.53%38 786
SEAGEN INC.6.06%33 601